Advances in LLM. Ofatumumab: a new agent for chronic lymphocytic leukemia.
Osterborg
Anders
A
Karolinska University Hospital, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
D000911:Antibodies, Monoclonal / Q000627:therapeutic use* / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20 / Q000276:immunology; D001665:Binding Sites; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018951:Antigens, CD20; C527517:ofatumumab